Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance

Lee,Sooyeun; Jang,Won‑Jun; Choi,Boyeon; Joo,Sang  Hoon; Jeong,Chul‑Ho

doi:10.3892/ol.2017.5940

Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance

Authors:
- Sooyeun Lee
- Won‑Jun Jang
- Boyeon Choi
- Sang Hoon Joo
- Chul‑Ho Jeong
View Affiliations

Affiliations: College of Pharmacy, Keimyung University, Dalseo, Daegu 42601, Republic of Korea, Department of Pharmacy, Catholic University of Daegu, Gyeongsan‑si, Gyeongbuk 38430, Republic of Korea
Published online on: March 28, 2017 https://doi.org/10.3892/ol.2017.5940
Pages: 3437-3444
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is one of the most lethal types of cancer, due to difficulty in early detection and the limited efficacy of available treatments. Erlotinib is used to inhibit the epidermal growth factor receptor for the treatment of pancreatic cancer; however, erlotinib resistance is a major issue and the mechanisms underlying the development of erlotinib resistance remain unclear. To better understand the alterations in tumor metabolism by acquired resistance to erlotinib, an erlotinib‑resistant pancreatic cancer cell line (HPAC‑ER) was established, followed by a comparison of the metabolic characteristics between these cells and their erlotinib-sensitive parental cells (HPAC). This comparison was accomplished through mass spectrometry-based targeted metabolic profiling. Five metabolite groups (acylcarnitines, amino acids and biogenic amines, glycerophospholipids, sphingolipids and monosaccharides) were semi‑quantified and compared statistically. These results revealed significant differences between the two groups of cells. A significant increase in the level of short‑chain acylcarnitines and selected lysophosphatidylcholines, and a significant decrease in the level of acyl‑alkyl‑phosphatidylcholines and one sphingolipid, were observed in the HPAC‑ER cells compared with the HPAC cells. The metabolic changes observed in the present study support the theory that there are increased metabolic demands in erlotinib‑resistant cancer, reflecting the changes in acetyl‑CoA‑associated and choline phospholipid metabolism. These findings will aid in elucidating the changes that occur in pancreatic cancer metabolism through the acquired resistance to erlotinib, and in the identification of biomarkers for the early detection of pancreatic cancer.

View Figures

View References

1	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
3	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
4	Bouhifd M, Hartung T, Hogberg HT, Kleensang A and Zhao L: Review: Toxicometabolomics. J Appl Toxicol. 33:1365–1383. 2013. View Article : Google Scholar : PubMed/NCBI
5	Cuperlović-Culf M, Barnett DA, Culf AS and Chute I: Cell culture metabolomics: Applications and future directions. Drug discovery today. 15:610–621. 2010. View Article : Google Scholar : PubMed/NCBI
6	Theodoridis GA, Gika HG, Want EJ and Wilson ID: Liquid chromatography-mass spectrometry based global metabolite profiling: A review. Anal Chim Acta. 711:7–16. 2012. View Article : Google Scholar : PubMed/NCBI
7	Freedman VH and Shin SI: Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium. Cell. 3:355–359. 1974. View Article : Google Scholar : PubMed/NCBI
8	Matuszewski BK, Constanzer ML and Chavez-Eng CM: Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 75:3019–3030. 2003. View Article : Google Scholar : PubMed/NCBI
9	Kerner J and Hoppel C: Fatty acid import into mitochondria. Biochim Biophys Acta. 1486:1–17. 2000. View Article : Google Scholar : PubMed/NCBI
10	Zammit VA, Ramsay RR, Bonomini M and Arduini A: Carnitine, mitochondrial function and therapy. Adv Drug Deliv Rev. 61:1353–1362. 2009. View Article : Google Scholar : PubMed/NCBI
11	Medina MA, Sánchez-Jiménez F, Márquez J, Quesada Rodríguez A and de Núñez Castro I: Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem. 113:1–15. 1992. View Article : Google Scholar : PubMed/NCBI
12	Sasada S, Miyata Y, Tsutani Y, Tsuyama N, Masujima T, Hihara J and Okada M: Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil. Oncol Rep. 29:925–931. 2013.PubMed/NCBI
13	Staubert C, Bhuiyan H, Lindahl A, Broom OJ, Zhu Y, Islam S, Linnarsson S, Lehtiö J and Nordström A: Rewired metabolism in drug-resistant leukemia cells: A metabolic switch hallmarked by reduced dependence on exogenous glutamine. J Biol Chem. 290:8348–8359. 2015. View Article : Google Scholar : PubMed/NCBI
14	Serizawa M, Kusuhara M, Zangiacomi V, Urakami K, Watanabe M, Takahashi T, Yamaguchi K, Yamamoto N and Koh Y: Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells. Anticancer Res. 34:2779–2787. 2014.PubMed/NCBI
15	Fujimura Y, Ikenaga N, Ohuchida K, Setoyama D, Irie M, Miura D, Wariishi H, Murata M, Mizumoto K, Hashizume M and Tanaka M: Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. Pancreas. 43:311–318. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ripps H and Shen W: Review: Taurine: A ‘very essential’ amino acid. Mol vis. 18:2673–2686. 2012.PubMed/NCBI
17	Bellance N, Pabst L, Allen G, Rossignol R and Nagrath D: Oncosecretomics coupled to bioenergetics identifies α-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes. Biochim Biophys Acta. 1817:2060–2071. 2012. View Article : Google Scholar : PubMed/NCBI
18	Peters MA, Walenkamp AM, Kema IP, Meijer C, de Vries EG and Oosting SF: Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. Drug Resist Updat. 17:96–104. 2014. View Article : Google Scholar : PubMed/NCBI
19	Beltowski J and Kedra A: Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep. 58:159–178. 2006.PubMed/NCBI
20	Davids M, Swieringa E, Palm F, Smith DE, Smulders YM, Scheffer PG, Blom HJ and Teerlink T: Simultaneous determination of asymmetric and symmetric dimethylarginine, L-monomethylarginine, L-arginine and L-homoarginine in biological samples using stable isotope dilution liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 900:38–47. 2012. View Article : Google Scholar : PubMed/NCBI
21	Martens-Lobenhoffer J and Bode-Böger SM: Quantification of L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: A step improvement in precision by stable isotope dilution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 904:140–143. 2012. View Article : Google Scholar : PubMed/NCBI
22	Li H, Zhou Y, Zhao A, Qiu Y, Xie G, Jiang Q, Zheng X, Zhong W, Sun X, Zhou Z and Jia W: Asymmetric dimethylarginine attenuates serum starvation-induced apoptosis via suppression of the Fas (APO-1/CD95)/JNK (SAPK) pathway. Cell Death Dis. 4:e8302013. View Article : Google Scholar : PubMed/NCBI
23	Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et al: Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
24	Cummings BS: Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol. 74:949–959. 2007. View Article : Google Scholar : PubMed/NCBI
25	Tripathi P, Kamarajan P, Somashekar BS, MacKinnon N, Chinnaiyan AM, Kapila YL, Rajendiran TM and Ramamoorthy A: Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A2, a potential therapeutic target. Int J Biochem Cell Biol. 44:1852–1861. 2012. View Article : Google Scholar : PubMed/NCBI
26	Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S and Podo F: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 65:9369–9376. 2005. View Article : Google Scholar : PubMed/NCBI